drugset / Trial / NCT06890416

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

NCT06890416

Phase 3 Completed 526 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

Timeline

Start
2025-04-04
Primary completion
2025-09-30
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HZ/su Vaccine Intramuscular
Subject RSVpreF Vaccine Intramuscular